Antibiotic Market Trends

Source 1
This the title of the source
- Generic antibiotic industries: Challenges and implied strategies with
regulatory perspectives
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3053506/
-those subtitle included in the same source
Generic Pharma Industries / Generic Medicines
History of Antibiotics
Generic Antibiotics in Cost Reduction
History of Generic Antibiotic Regulations in USA
Global Scenario of Antibiotics

Source 2
- Can biotech deliver new antibiotics?
https://www.msu.edu/course/mmg/445/Lecture%20Notes_files/BarettJS.pdf
Source 3
This source can be use an example
http://www.liquisearch.com/statin/history

Statin - History
History
In 1971, Akira Endo, a Japanese biochemist working for the pharmaceutical company Sankyo, began
the search for a cholesterol-lowering drug. Research had already shown that cholesterol is mostly
manufactured by the body in the liver, using an enzyme known as HMG-CoA reductase. Endo and his
team reasoned that certain microorganisms may produce inhibitors of the enzyme to defend
themselves against other organisms, as mevalonate is a precursor of many substances required by
organisms for the maintenance of their cell wall (ergosterol) or cytoskeleton (isoprenoids). The first
agent they identified was mevastatin (ML-236B), a molecule produced by the fungus Penicillium
citrinum.
Mevastatin was never marketed, because of its adverse effects of tumors, muscle deterioration, and
sometimes death in laboratory dogs. P. Roy Vagelos, chief scientist and later CEO of Merck & Co, was
interested, and made several trips to Japan starting in 1975. By 1978, Merck had isolated lovastatin

(mevinolin, MK803) from the fungus Aspergillus terreus, first marketed in 1987 as Mevacor.
A link between cholesterol and cardiovascular disease, known as the lipid hypothesis, had already
been suggested. Cholesterol is the main constituent of atheroma, the fatty lumps in the wall of
arteries that occur in atherosclerosis and, when ruptured, cause the vast majority of heart attacks.
Treatment consisted mainly of dietary measures such as a low-fat diet, and poorly tolerated medicines
such as clofibrate, cholestyramine and nicotinic acid. Cholesterol researcher Daniel Steinberg writes
that while the Coronary Primary Prevention Trial of 1984 demonstrated that cholesterol lowering could
significantly reduce the risk of heart attacks and angina, physicians, including cardiologists, remained
largely unconvinced.
To market statins effectively, Merck had to convince the public about the dangers of high cholesterol,
and doctors that statins were safe and would extend lives. As a result of public campaigns, people
became familiar with their cholesterol numbers and the difference between "good" and "bad"
cholesterol, and rival pharmaceutical companies began producing their own statins, such as
pravastatin (Pravachol), manufactured by Sankyo and Bristol-Myers Squibb. In April 1994, the results
of a Merck-sponsored study, the Scandinavian Simvastatin Survival Study or "4S", were announced.
Researchers tested simvastatin, later sold by Merck as Zocor, on 4,444 patients with high cholesterol
and heart disease. After five years, the study concluded that patients saw a 35-percent reduction in
their cholesterol, and their chances of dying of a heart attack were reduced by 42 percent. In 1995,
Zocor and Mevacor both made Merck over US$1 billion. Endo was awarded the 2006 Japan Prize, and
the Lasker-DeBakey Clinical Medical Research Award in 2008.